News

For the past five months, Mr Cuesta has been overseeing the region in an acting capacity. Mr Cuesta joined the company in August 2005 as country director for

Christopher Menard, currently Phase Forward’s vice president of finance, will succeed Weismann as CFO at that time. After June 1, 2009 Weismann will serve in a part-time capacity

BioMarin Pharmaceutical has announced results from its Phase II multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral arterial disease. There was no statistical

This technology is based on the findings of a study led by Jean-Claude Tardif at the Montreal Heart Institute research center in Canada. In Dr Tardif’s placebo-controlled study

Most recently, Mr Sneider served as CFO of NimbleGen Systems. Prior to NimbleGen, Mr Sneider was CFO of Third Wave Technologies. Mr Sneider holds a BBA and JD

The new dosing strengths, 45mg and 75mg, complement the currently available 30mg, 60mg, 90mg and 120mg dosages. Avinza is a long-acting opioid for patients with moderate to severe

The new offices located in Kiev and Bratislava will support staff in Ukraine and Slovakia, including Covance’s regional network of field-based clinical research associates throughout central and eastern

Lamotrigine chewable tablets, marketed by GlaxoSmithKline as Lamictal chewable dispersible tablets, is a prescription pharmaceutical product used in treating seizures. Taro previously filed a ‘Paragraph IV’ certification challenging

ESBATech, a developer of antibody fragment therapeutics, has initiated a Phase Ib/IIa study in patients undergoing cataract surgery. This study is designed to evaluate the safety, tolerability, and